Dec 4 (Reuters) - INNATE PHARMA:
* ANNOUNCED ON MONDAY UPDATED RESULTS THAT SUPPORT ADVANCEMENT OF IPH4102 IN REFRACTORY SÉZARY SYNDROME
* DIFFERENTIATING PROFILE OF IPH4102 CONFIRMED: HIGH AND DURABLE RESPONSE, FAVORABLE SAFETY PROFILE WITH LONG-TERM FOLLOW-UP AND SUBSTANTIAL IMPROVEMENT IN QUALITY OF LIFE
* EXPECTS TO INITIATE A GLOBAL PHASE II STUDY (“TELLOMAK”) IN DIFFERENT SUBTYPES OF T-CELL LYMPHOMAS IN THE FIRST HALF OF 2019
Source text for Eikon:
Further company coverage: (Gdynia Newsroom)
